

6. Literatur

1. ADAMS, G.; SCHIER, R.; McCALL, A.; SIMMONS, H.; HORAK, E.; ALPAUGH, R.; MARKS, J.; WEINER, L.: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Cancer Res. **61**, 4750, 2001
2. AHRENS, N.; KINGREEN, D.; SELTSAM, A.; SALAMA, A.: Treatment of refractory autoimmune haemolytic anaemia With anti-CD20 (Rituximab).
British Journal of Haematology. **114**, 244-245, 2001
3. AIZAWA, S.; NAKANO, H.; ISHIDA, T.: Tumor necrosis factor receptor-associated factor TRAF5 and TRAF2 are involved in CD30-mediated NF- χ B activation.
J. Biol. Chem. **272**, 2042-2045, 1997
4. ALTSCHUL, S.; GISH, W.; MITTLER, W.; MYERS, E.; LIPMAN, D.: Basic local search alignment search tools.
J. Mol. Biol., 1990
5. AMELOOT, P.; FIERS, W.; DE BLESER, P.; WARE, C. ; VANDENABEELE, P. ; BROUCKAERT, P. : Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptorselective mutants.
J. Biol. Chem. **40**, 37426, 2001
6. ANAGNOSTOPOULOS, I.; HANSMANN, M.; FRANSSILA, K.; JAFFE, E.; HAN, J.; VAN KRIEKEN, J.; POPPEMA, S.; MARAFIOTI, T.; FRANKLIN, J.; SEXTRO, M.; DIEHL, V.; STEIN, H.: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
Blood. **96**, 1889-1899, 2000
7. ANSEN, S.; ENGERT, A.; WOLF, J; SIEBER, M.; PAULUS, U.; DIEHL, V.: Deutsche Hodgkin-Lymphom-Studiengruppe (DHSG)- 20 Jahre Diagnostik, Therapie und Nachsorge von Patienten mit Morbus Hodgkin.
Onkologie. **24**, 35-48, 2001
8. ARMITAGE, J.: Treatment strategies for patients with relapsed or refractory Hodgkin's disease.
Ann. Oncol. **6**, 517-518, 1995
9. ARMITAGE, J.: Tumor necrosis factor receptor superfamily members and their ligands.
Curr. Opin. Immunol. **6**, 407-413, 1994
10. BAUER S.; ADRIAN, N.; WILLIAMSON, B.; PANOUSIS, C.; FADLE, N.; SMERD, J.; FETTAH, I.; SCOTT, A.; PFREUNDSCHUH, M.; RENNEN, C.: Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein.
J. Immunol. 3930, 2004
11. BAZZONI, F.; BEUTLER, B.: The tumor nekrosis factor ligand and receptor families.
New Engl. J. Med. **334**, 1717-1725, 1996

12. BEG, A.; BALTIMORE, D.: An essential role for NF- κ B in preventing TNF- α induced cell death.
Science. **274**, 782-784, 1996
13. BELYAVSKY, A.; VINOGRADOVA, T.; RAJEWSKY, K.: PCR-based cDNA library construction: general cDNA libraries at the level of a few cells.
Nucleic Acids Res. **17(8)**, 2919-2932, 1989
14. BEUTLER, B.; GREENWALD, D.; HULMES, J.; CHANG, M.; PAN, Y.; MATHISON, J.; ULEVITCH, R.; CERAMI, A.: Identità of tumor necrosis factor and the macrophage-secreted factor cachetin.
Nature. **316**, 552-554, 1985
15. BEYAERT, R.; FIERS, W.: Molecular mechanisms of tumor necrosis factor-induced cytotoxicity: what we do understand and what we do not.
FEBS. Lett. **340**, 9-16, 1994
16. BONADONNA, G.; SANTORO, A.: ABVD chemotherapy in the treatment of Hodgkin's Disease.
Cancer Treat Rev. **9**, 21-35, 1982
17. BONAVIDA, B.; NG, C.; JAZIREHI, A.; SCHILLER, G.; MIZUTANI, Y.: Selectivity of TRAI-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics.
Int. J. Oncol. **15**, 793-802, 1999
18. BUSKE, C.; ENGERT, A.; SCHNELL, R.; DIEHL, V.; HIDDEMAN, W.: Monoklonale Antikörper in der Therapie maligner Lymphome.
Internist. 1998
19. BUSKE, C.; FEURIG-BUSKE, M.; ANTONCHUK, J.; ROSTEN, P.; HOGGE, D.; EAVES, C.; HUMPHRIES, R.: Overexpression of HOXA 10 perturbs human lymphomyelopoiesis in vitro and in vivo.
Blood. **97**, 2286, 2001
20. CANELLOS, G.; ANDERSON, J.; PROPERT, K.; GREEN, M.; GOTTLIEB, A.; PETERSON, M.: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD.
N. Engl. J. Med. **327**, 1478-1484, 1992
21. CARSWELL, E.; OLD, L.; KASSEL, R.; GREEN, S.; FIORE, N.; WILLIAMSON, B.: An endotoxin-induced factor that causes necrosis of tumors.
Proc. Natl. Acad. Sci. USA. **72**, 3666-3670, 1975
22. CHEN, C.; OKAYAMA, H.: High-Efficiency Transformation of Mammalian Cells by Plasmid DNA.
Mol. Cell. Biol. **7**, 2745-2752, 1987
23. CHINNAIYAN, A.; O'ROUKE, K.; TEWARI, M.; DIXIT, V.: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.
Cell. **81**, 505-512, 1995

24. CHRIST, O.; SEITER, S.; MATZKU, S.; BURGER, C.; ZOLLER, M.: Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. *Clin. Cancer Res.* **7**, 985, 2001
25. CLYNES, R; TOWERS, T.; PRESTA, L.; RAVETCH, J.: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat.Med.* **6**, 443-446, 2000
26. COIFFIER, B.; HAIOUN, C.; KETTERER, N.; ENGERT, A.; TILLY, A.; MA, D.; LISTER, A.; RADFORD, J.A.; DIEHL, V.; REYES, F.: Rituximab (anti-CD20 monoklonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood.* **92**, 1927- 1932, 1998
27. COIFFIER, B.; LEPAGE, E.; BRIERE, J.; HERBRECHT, R; TILLY, H.; SALLES, G.; REYES, P.; LEDERLIN, P.; GISSELBRECHT, C.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. *New Engl. Journal of Med* **346**, 235-242, 2002
28. COLEY, W.: The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the *Streptococcus erysipelas* and the *Bacillus prodigius*). London: John Bale & Sons Publishers, 1-48, 1909
29. COLOMA, M.; MORRISON, S.: Design and production of novel tetravalent bispecific antibodies. *Nat. Biotechnol.* **15**, 159, 1997
30. COLOMBAT, P.; SALLES, G.; BROUSSE, N.; DELWAIL, V.; HAIOUN, C.; SEBBAN, C.; MILPIED, N.; BOUE, F.; LEDERLIN, P.; NAJMAN, A.; MONTESTRUC, F.; BENZOHR, A.; SOLAL-CELIGNY, P.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with low tumor burden: clinical and molecular evaluation. *Blood.* **97**, 101-106, 2001
31. CURNIS, F.; SACCHI, A.; BORGNA, L.; MAGNI, F.; GASPARRI, A.; CORTI, A.: Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase (CD13). *Nat. Biotechnol.* **18**, 1185, 2000
32. DEANS, J.; LI, H.; POLYAK, M.: CD20-mediated apoptosis: signalling through lipid rafts. *Immunology.* **107(2)**, 176-182, 2002
33. DECLERQ, W; DENECKER, G.; FIERS, W.; VANDENABEELE, P.: Cooperation of both TNF receptors in inducing apoptosis. *J. Immunol.* **161**, 390-399, 1998
34. DE VITA, V.; SERPICK, A.; CARBONE, P.: Combination chemotherapy in the treatment of advanced Hodgkin's disease. *Ann. Intern. Med.* **73**, 881, 1970

35. DIEHL, V.; FRANKLIN, J.; PFREUNDSCHUH, M.; LATHAN, B.; PAULUS, U.; TESCH, H.; DORKEN, B.; DUHMKE, E.; LOEFFLER, M.; German Hodgkin's Lymphoma Study Group: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N. Engl. J. Med.* **348**, 2386, 2003
36. DIEHL, V.; FRANKLIN, J.; HANSENCLEVER, D.: BEACOPP, a new dose-escalated and accelerated regime, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. *Clin. Oncol.* **16**, 3810-3821, 1998
37. DIEHL, V.; WOLF, J.; WALSHE, R.; TESCH, H.; LÖFFLER, M.: Die Therapie des Morbus Hodgkin. *Internist.* **38**, 917-926, 1998
38. DILLMAN, R.: Monoclonal antibody therapy for lymphoma: an update. *Cancer Pract.* **9**, 71-80, 2001
39. DILLMAN, R.: Antibodies as cytotoxic therapy. *J. Clin. Oncol.* **12**, 1497-1515, 1994
40. DUCKETT, C.; THOMPSON, C.: Cd30-dependant degranulation of TRAF2: implications for negative regulation of TRAF signalling and the control of cell survival. *Genes Dev.* **11**, 2810-2821, 1997
41. DÜRKOP, H.; OBERBARNSCHEIDT, M.; LATZA, U.; BULFONE-PAUS, S.; KRAUSE, B.; POHL, T.; STEIN, H.: Structure of Hodgkin's lymphoma-associated human CD30 gene and influence of microsatellite region on its expression in CD30 (+) cell lines. *Biochem. Biophys. Acta.*, 2001
42. ELLIS, T.; SIMMS, P.; SLIVNICK, D.; JACK, H.; FISHER, R.: CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+T cells. *J. Immunol.* **151**, 2380-2389, 1996
43. ENGERT, A.; BURROWS, F.; JUNG, W.: Evaluation of ricin A chain –containing immunotoxins directed against the CD30 antigen as potential reagents in the treatment of Hodgkin's disease. *Cancer Res.* **50**, 84-88, 1990
44. FERRERO, E.; ZOCCHI, M.; MAGNI, E.; PANZERI, M.; CURNIS, F.; RUGARLI, C.; FERRERO, M.; CORTI, A.: Roles of tumor necrosis factor p55 and p75 receptors in TNF- α -induced vascular permeability. *Am. J. Physiol.* **281**, C1173, 2001
45. FLIEGER, D.; RENOTH, S.; BEIER, I.; SAUERBRUCH, T.; SCHMIDT-WOLF, I.: Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. *Cell Immunol.* **204**, 55-63, 2000

46. FOSS, H.; MARAFIOTI, T.; STEIN, H.: Hodgkin Lymphome. Pathologie. 2000
47. FUJIMORI, K.; COVELL, D.; FLETSCHER, J.; WEINSTEIN, J.: A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. **31(7)**, 1191, 1990
48. GEORGOPOULOS, C.; WELSCH, W.: Role of the major heat shock proteins as molecular chaperones. Annu. Rev. Cell Biol. **9**, 601-634, 1993
49. GILFILLAN, M.; NOEL, P.; PODACK, E.; REINER, S.; THOMPSON, C.: Expression of the costimulatory receptor CD30 is regulated by both Cd28 and cytokines. J. Immunol. **160**, 2180-2187, 1998
50. GLENN, L.; KUMAR, P.: The residual mediastinal mass following radiation therapy for Hodgkin's disease. Am. J. Clin. Oncol. **14**, 16, 1991
51. GRELL, M.; ZIMMERMANN, G.; GOTTFRIED, E.: Induction of cell death by tumor necrosis factor (TNF) receptor2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored. EMBO J. **18**, 3034-3043, 1999
52. GRELL, M.; WAJANT, H.; ZIMMERMANN, G.; SCHEURICH, P.: The type I receptor (CD 120a) is the high affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA. **95**, 570, 1998
53. GRELL, M.; DOUNI, E.; WAJANT, H.; LOHDEN, M.; CLAUSS, M.; MAXEINER, B.; GEORGOPOULOS, S.; LESSLAUER, W.; KOLLIAS, G.; PFIZENMAIER, K.; SCHEURICH, K.: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. **83**, 793-802, 1995
54. GRELL, M.; SCHEURICH, P.; MEAGER, A.; PFITZENMAIER, K.: TR60 and TR80 Tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res. **12**, 143, 1993
55. GRUSS, H.; DOWER, S.: Tumor necrosis factor ligand super family: involvement in the pathology of malignant lymphomas. Blood. **85**, 3378-3404, 1995
56. GRUSS, H.; BOIANI, N.; WILLIAMS, D.; ARMITAGE, R.; SMITH, C.; GOODWIN, R.: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. **83**, 2045-2056, 1994
57. GUO, D.; SHEN, B.; DONG, X.; QIU, Q.; XU, X.: Creation of a high cytotoxic active human tumor necrosis factor having a truncated and more basic amino terminus. Biochem. Biophys. Res. Commun. **207**, 927, 1995

58. HAN, H.; FUORTES, M.; NATHAN, C.: Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumor necrosis factor: separation of signals for the respiratory burst and degranulation. *J. Exp. Med.* **197**, 63, 2003
59. HARTMANN, F.; RENNER, C.; JUNG, W.; DA COSTA, L.; TEMBRINK, S.; HELD, G.; SEK, A.; KÖNIG, J.; BAUER, S.; KLOFT, M.; PFREUNDSCHUH, M.: Anti-CD16/CD30 Bispecific Antibody Treatment for Hodgkin's Disease: Role of Infusion Schedule and Costimulation with Cytokines. *Clin. Cancer Res.* **7**, 1873-1881, 2001
60. HIGUCHI, R.; KWOK, S.: Avoiding false positives with PCR. *Nature.* **339**, 237-238, 1989
61. HOLMES, D.; QUINGLEY, M.: A rapid boiling method for the preparation of bacterial plasmids. *Anal. Biochem.* **114**, 193-197, 1981
62. HORN-LOHRENS, O.; TIEMANN, M.; LANGE, H.: Shedding of the soluble of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new specific antibody (Ki-4). *Int. Cancer.* **60**, 539-544, 1995
63. HSU, H.; XIONG, J.; GOEDDEL, D.: The TNF receptor 1-associated protein TRADD signals cell death and NF- κ B activation. *Cell.* **81**, 495-504, 1995
64. JOSTING, A.; KATAY, I.; RUEFFER, U.; WINTER, S.; TESCH, H.; ENGERT, A.; DIEHL, V.; WICKRAMANAYAKE, P.: Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with a high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy. *Ann. Oncol.* **289**, 95, 1998
65. JOSTING, A.; BEHRINGER, K.; ENGERT, A.; DIEHL, V.: Modern pharmacotherapy of Hodgkin's disease. *Internist.* **45**, 93, 2004
66. KAIN, S.; COPELAND, TS.; LEAHY, M.: Treatment of refractory autoimmune (acquired) Haemophilia with Anti-CD20 (Rituximab). *British Journal of Haematology.* **119**, 572-580, 2002
67. KANZLER, H.; KUPPERS, R.; HAUSMANN, M.; RAJEWSKY, K.: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. *J. Exp. Med.* **184**, 1495, 1996
68. KAPLAN, H.: Role of intensive radiotherapy in the management of Hodgkin's disease. *Cancer.* **19**, 356, 1966

69. KITSON, J.; RAVEN, T.; JIANG, Y.: A death domain-containing receptor that mediates apoptosis.
Nature. **384**, 372-375, 1996
70. KÖHLER, G.; MILSTEIN, C.: Continuous cultures of fused cell secreting antibody of predefined specificity.
Nature. **256**, 495, 1975
71. KRIEGLER, M.; PEREZ, C.; DE FAY, K.; ALBERT, I. ; LU, S. : A novel form of TNF cachectin is a cell surface cytotoxic transmembrane protein : ramifications for the complex physiology of TNF.
CELL. **53**, 45, 1988
72. KRIPPNER-HEIDENREICH, A.; TÜBING, F.; BRYDE, S.; WILLI, S.; ZIMMERMANN, G.; SCHEURICH, P.: Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction.
J. Biol. Chem. **277**, 44155, 2002
73. KROSNICK, J.; MELNTOSH, J.; MULE, J.; ROSENBERG, S.: Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice.
Cancer Immunol. Immunother, **30**, 133,1989
74. LAEMMLI, U.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature. 1970
75. LAEMMLI, U.; KING, J.: Polypeptides of the tail fibres of the bacteriophage T4.
J. Mol. Biol., 1971
76. LEE, S.; PARK, C.; CHOI, Y.: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors.
J. Exp. Med. **183**, 669-674, 1996
77. LEVINE, T.; PESTRONK, A.: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.
Neurology. **52**, 1701-1704, 1999
78. LIU, Z.; HSU, H.; GOEDDEL, D.; KARIN, M.: Dissection of TNF receptor1 effector functions: JNK activation is not linked to apoptosis, while NF- κ B activation prevents cell death.
Cell. **87**, 565-576, 1996
79. LOCKSLEY, R.; KILLEEN, N.; LENARDO, M.: The TNF and TNF receptor superfamilies: integrating mammalian biology.
Cell. **104**, 487, 2001
80. LONGO, D.: The use of chemotherapy in the treatment of Hodgkin's Disease.
Sem. Oncol. **17**, 716-735, 1986

81. LOWELL, C.; FUMAGALLI, L.; BERTON, G.: Deficiency of Src family kinases p59/61 and p58 results in defective adhesion-dependent neutrophil functions.
J. Cell Biol. **133**, 895, 1996
82. MALONEY, D.G.; GRILLO-LOPEZ, A.J.; WHITE, C.A.; BODKIN, D.; NEIDHART, J.; FOON, K.; LILES, T.; WAY, K.; ROYSTON, I.; DAVIS, T.; LEVRY, R.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Blood, **90**, 2188-2195, 1997
83. MEISSNER, P.; PICK, H.; KULANGARA, A.; CHATELLARD, P.; FRIEDRICH, K.; WURM, F.: Transient gene expression: recombinant protein production with suspension-adapted HEK293 EBNA cells.
Biotechnol. Bioeng. **75**, 197, 2001
84. MESSINEO, C.; JAMERSON, H.; HUNTER, E.; BRAZIEL, R.; BAGG, A.; IRVING, S.; COSSMAN, J.: Gene Expression by Single Reed-Sternberg Cells: Pathways of Apoptosis and Activation.
Blood. **91**, 2443-2451, 1998
85. MILLER, R.: Treatment of B-cell lymphoma with monoclonal anti-idiotypic antibody.
N. Engl. J. Med. **306**, 517-522, 1982
86. MIR, S.; RICHTER, B.; DUCKETT, C.: Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.
Blood. **96**, 4307-4312, 2000
87. OFFRINGA, R.; VAN DER BURG, S.; OSSENDORP, S.; TOES, R.; MELIEF, C.: Design and evaluation of antigen-specific vaccination strategies against cancer.
Curr. Opin. Immunol. **12**, 576-582, 2000
88. OLD, L.: Tumor necrosis factor: polypeptide mediator network.
Nature. **326**, 330, 1987
89. OVERWIJK, W.; LEE, D.; SURMAN, D.: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Proc. Natl. Acad. Sci. USA. **96**, 2982-2987, 1999
90. PAN, G.; O'ROUKE, K.; CHINNAIYAN, A.: The receptor for the cytotoxic ligand TRAIL.
Science. **276**, 111-113, 1997
91. PEREZ, C.; ALBERT, K.; DE FAY, K.; ZACHARIADES, N.; GOODING, L.; KRIEGLER, M.: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact.
Cell. **63**, 251, 1990

92. PETERSEN, C. ; NYKJAER, A.; CHRISTIANSEN, B.; HEICKENDORFF, L.; MORGENSEN, S.; MOLLER, B.: Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?
Eur. J. Immunol. 19, 1887, 1989
93. REHWALD, U.; SCHULZ, H.; REISER, M.; SIEBER, M.; STAAK, J.; RUDIGER, T.; DIEHL, V.; ENGERT, A.; German Hodgkin Lymphoma Study Group (GHSG): Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of phase 2 trial of the German Hodgkin Lymphoma Study Group.
Blood. **101**, 420, 2003
94. RENNER, C.; HARTMANN, F.; PFREUNDSCHUH, M. Immuntherapeutische Strategien zur Behandlung solider Tumoren.
Dt. Ärzteblatt. **99**, 850-858, 2002
95. RUEGG, C.; YILMAZ, A.; BIELER, G.; BAMAT, J.; CHAUBERT, P.; LEJEUNE, F.: Evidence for the involvement of endothelial cell integrin $\alpha\beta 3$ in the disruption of the tumor vasculature induced by TNF and INF- γ .
Nat. Med. **4**, 408, 1998
96. SAIKI, R.; SCHARF, S.; FALOONA, F.; MULLIS, K.; HORN, G.; ERLICH, G.; ARNHEIM, N.: Enzymatic amplification of β -globin genomic sequences and restriction site analysis for diagnosis of sickle cell anaemia.
Science. **230**, 1350, 1985
97. SANGER, F.; NICKLEN, S.; COULSON, A.: DNA Sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. **74**, 5463-5467, 1977
98. SCALLON, B.; CAI, A.; SOLOWSKI, N.; ROSENBERG, A.; SONG X.; SHEALY, D.; WAGNER, C.: Binding and functional comparisons of two types of tumor necrosis factor antagonists.
J. Pharmacol. Exp. Ther. 301, 418, 2002
99. SCHMIDT, E.; BINDER, K.; GRELL, M.; SCHEURICH, P.; PFIZENMAIER, K.: Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor α .
Blood. **86**, 123, 1995
100. SCHNELL, R.; STAAK, O.; BORCHMANN, P.; SCHWARTZ, C.; MATTHEY, B.; HANSEN, H.; GHETIE, V.; VITETTA, E.; DIEHL, V.; ENGERT, A.: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD 30+ Hodgkin's and non-Hodgkin's lymphoma
Clin. Cancer Res. **8**, 1779-1786, 2002
101. SCHNELL, R.; LINNATZ, C.; KATOUIZI, A.: Development of anew ricin rich A-chain immunotoxin with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Int. J. Cancer. **63**, 238-244, 1995

102. SCHÜTZE, S.; MACHLEIDT, D.; ADAM, D.; SCHWANDNER, R.; WIEGMANN, K.; KRUSE, M.; HEINRICH, M.; WICKEL, M.; KRÖNKE, M.: Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling.
J. Biol. Chem. **274**, 10203, 1999
103. SCHULZE-OSTHOFF, K.; FERRARI, D.; MAREK, L.; WESSELBORG, S.; PETER, M.: Apoptosis signaling by death receptors.
Eur. J. Biochem. **254**, 439-459, 1998
104. SCHWAB, U.; STEIN, H.; GERDES, J.: Production of a monoklonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.
Nature. **299**, 65-67, 1982
105. SHAN, D.; LEDBETTER, J.; PESS, O.: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Cancer Immunol. Immunother. **48**, 673-683, 2000
106. SHAPIRO, A.; VINUELA, E.; MAIZEL, J.: Molecular weight estimation of polypeptide chains by electrophoretics in SDS polyacrylamid gels.
Biochem. Biophys. Research Commun., 1967
107. SIEBER, M.; RÜFFLER, U.; DIEHL, V.: Aktuelle Therapiestrategien beim Morbus Hodgkin. Morbus Hodgkin und Non-Hodgkin-Lymphome, 2. überarbeitete Auflage, 97-109, 1998
108. SIEBER, M.; Tesch, H.; PFISTNER, B.; RUEFFER, U.; LATHAN, B.; KOCH, T.; PFREUNDSCHUH, M.; LOEFFLER, M.; ENGERT, M.; WOLF, J.; KIRCHNER, H.; DOELKEN, G.; MUNKER, R.; KOCH, P.; HERRMANN, R.; GREIL, R.; ANSELMO, A.; DIEHL, V.: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
J. Clin. Oncol. **20**, 476-84, 2002
109. SMITH, C.; GRUSS, H.; DAVIS, T.: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.
Cell. **73**, 1349-1360, 1993
110. SPARLING, T.; ANDICEVIC, M.; WASS, H.: Remission of cold hemagglutinin disease induced by Rituximab therapy.
CMAJ. **164** (10), 1405, 2001
111. SOUTHERN, E.: Detection of specific sequences among DNA fragments separated by gel electrophoresis.
J. Mol. Biol. **98(3)**, 503-517, 1975
112. STASI, R.; PAGANO, A.; STIPA, E.; AMADORI, S.: Rituximab chimeric anti-CD20 monoklonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Blood. **98**, 952-957, 2001

113. STIEFENHAGEN, P.: Morbus Hodgkin-Aktuelle Aspekte zur Pathogenese und Therapie. Internist. **39**, 668-674
114. SUN, Y.; PASCHEN, A.; SCHADENDORF, D.: Cell-based vaccination against melanoma-background, preliminary results and perspective. J. Mol. Med. **77**, 593-608, 1999
115. SUTO, R.; SRIVASTAVA, P.: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. **269**, 1585-1588, 1995
116. SWAIN; S.: T cell subsets and the recognition of MHC class. Immunol. Rev. **74**, 129-142, 1983
117. TARTAGLIA, L.; WEBER, R.; FIGARI, I.; REYNOLDS, C.; PALLADINO, M.; GOEDDEL, D.: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. **88**, 9292-9296, 1991
118. TOWBIN, H.; STAHELIN, T.; GORDON, J.: Electrophoretic transfer of proteins from polyacrylamid gels to nitrocellulose sheets: procedure and applications. Proc. Natl. Acad. Science, 1979
119. VAN ANTWERP, D.; MARTIN, S.; KAFRI, T.; GREEN, D.; VERMA, I.: Suppression of TNF- α -induced apoptosis by NF- κ B. Science. **274**, 787-789, 1996
120. VASSALLI, P.: The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. **10**, 411-452, 1992
121. WAHL, A.; KLUSSMAN, K.; THOMPSON, J.; CHEN, J.; FRANCISCO, L.; RISDON, G.; CHACE, D.; SIEGHALL, C.; FRANCISCO, J.: The Anti-CD 30 Monoclonal Antibody SGN 30 Promotes Growth Arrest and DANN Fragmentation in Vitro and Affects Antitumor Activity in Models of Hodgkin`s Disease. Cancer Research. **62**, 3736-3742, 2002
122. WARZOCHA, K.; BIENVENU, J.; RIBEIRO, P.; MOULLET, I.; DUMONTET, C.; NEIDHARDT-BERARD, E.; COIFFIER, B.; SALLES, G.: Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin`s disease patients. Br. J. Cancer. **77**, 2357-2362, 1998
123. WATSON, F.; GASMI, L., EDWARDS, S.: Stimulation of intracellular Ca²⁺ levels in human neutrophils by soluble immune complexes: functional activation of Fc γ RIIIb during priming. J. Biol. Chem. **272**, 17944, 1997
124. WIGLER, M.; SILVERSTEIN, S.; LEE, L.; PELLICER, A.; CHENG, Y.; AXEL, R.: Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell. **11**, 223-232, 1977

125. WRIGHT, P.; WYNFORD-THOMAS, D.: The polymerase chain reaction: miraclal or mirage? A critical review of its uses and limitations in diagnostic and research. Pathol., 1990
126. YAFFE, M.; XU, J.; BURKE, P.; FORSE, R.; BROWN, G.: Priming of the neutrophil respiratory burst is species dependent and involves MAP kinase activation. Surgery, **126**, 248, 1999